

Key University Research Statistics

August Fiscal Year 2022 & 2023

| | Proposals | | |
|-----------------|-----------------|-----------------|----------|
| Fiscal Year | FY2022 | FY2023 | % Change |
| Count Submitted | 4,454 | 4,818 | 8.17% |
| Amount | \$1,497,807,249 | \$1,709,369,954 | 14.12% |
| Direct Amount | \$1,122,613,615 | \$1,290,447,815 | 14.95% |
| Indirect Amount | \$375,193,634 | \$418,922,139 | 11.65% |

| | Awards | | | | | |
|----------------------------------|---------------------|---------------------|-----------------|--|--|--|
| Fiscal Year | FY2022 | FY2023 | % Change | | | |
| Count Awarded | 3,832 | 4,065 | 6.08% | | | |
| Amount | \$944,491,143 | \$1,064,932,260 | 12.75% | | | |
| Direct Amount | \$711,382,844 | \$809,658,150 | 13.81% | | | |
| Indirect Amount | \$233,108,299 | \$255,274,110 | 9.51% | | | |
| Federal Direct | \$448,098,443 | \$509,428,409 | 13.69% | | | |
| Federal Indirect | \$156,718,989 | \$174,962,641 | 11.64% | | | |
| Federal Flow-Through | \$130,531,298 | \$143,055,776 | 9.60% | | | |
| PHS Direct | \$416,308,995 | \$466,105,795 | 11.96% | | | |
| PHS Indirect | \$148,966,907 | \$163,915,577 | 10.03% | | | |
| NIH Direct | \$390,251,955 | \$402,599,491 | 3.16% | | | |
| NIH Indirect | \$142,891,098 | \$154,346,662 | 8.02% | | | |
| Grants | \$712,125,566 | \$762,750,247 | 7.11% | | | |
| Contracts | \$117,786,015 | \$177,304,860 | 50.53% | | | |
| Subcontracts | \$24,991,030 | \$22,472,471 | -10.08% | | | |
| Subgrants | \$89,551,282 | \$102,346,789 | 14.29% | | | |
| Other | \$37,250 | \$57,892 | 55.41% | | | |
| Trials ¹ | \$98,028,779 | \$82,321,168 | -16.02% | | | |
| | Sponsor Type | +01,011,100 | 2010270 | | | |
| Corporate | \$88,172,896 | \$91,439,904 | 3.71% | | | |
| Federal | \$604,817,432 | \$684,391,050 | 13.16% | | | |
| Foreign | \$12,191,366 | \$14,316,549 | 17.43% | | | |
| Private | \$141,179,785 | \$171,639,487 | 21.58% | | | |
| State | \$16,421,750 | \$18,370,694 | 11.87% | | | |
| | | | | | | |
| University Flow-through | \$81,707,914 | \$84,774,575 | 3.75% | | | |
| _ | Purpose | | | | | |
| Research | \$745,023,078 | \$866,243,271 | 16.27% | | | |
| Training | \$40,309,276 | \$49,384,949 | 22.52% | | | |
| Other | \$159,158,789 | \$149,304,040 | -6.19% | | | |
| | | | | | | |
| | Award Type | | | | | |
| Fiscal Year | FY2022 | FY2023 | % Change | | | |
| New | \$311,165,606 | \$381,318,298 | 22.55% | | | |
| | ,, | | | | | |
| Count | 1,350 | 1,556 | 15.26% | | | |
| 04'4' | #404 440 105 | #400 701 151 | 4 = 000/ | | | |
| Continuation | \$424,449,100 | \$489,726,626 | 15.38% | | | |
| Count | 1,269 | 1,374 | 8.27% | | | |
| Renewal | · | | | | | |
| Vettemat | \$25,701,184 | \$33,071,615 | 28.68% | | | |
| Count | 58 | 70 | 20.69% | | | |
| Count | 36 | 70 | 40.09 /0 | | | |
| Supplemental | \$183,175,254 | \$160,815,721 | -12.21% | | | |
| | | . , ., .– | | | | |
| Count | 1155 | 1065 | -7.79% | | | |
| Data source: EBI as of 9/13/2023 | | | | | | |

| 2023 | | | |
|--|--------------------------------|--------------------------------|------------------|
| | Expenses | | |
| Fiscal Year | FY2022 | FY2023 | % Change |
| Direct Amount | \$602,439,367 | \$690,300,245 | 14.58% |
| Indirect Amount | \$189,192,164 | | 12.65% |
| | | \$213,120,268 | |
| Federal Direct | 390,845,958 | 444,456,808 | 13.72% |
| Federal Indirect | \$136,202,805 | \$151,607,661 | 11.31% |
| Federal Flow-Through PHS Direct | \$96,355,487 \$359,614,112 | \$115,696,526 \$412,772,687 | 20.07% 14.78% |
| | | | |
| PHS Indirect Grants | \$129,089,461 \$605,638,701 | \$144,920,248 \$690,632,236 | 12.26% 14.03% |
| | | <u> </u> | |
| Contracts Subcontracts | \$80,016,277 \$17,412,975 | \$90,339,381 \$20,723,652 | 12.90% 19.01% |
| Subgrants | \$72,033,028 | \$87,960,511 | 22.11% |
| Other | \$16,493,684 | \$13,749,568 | -16.64% |
| Clinical Trials | \$72,251,906 | \$67,805,904 | -6.15% |
| | Sponsor Type | 401,000,201 | 0.10% |
| Corporate | \$67,258,929 | \$64,993,981 | -3.37% |
| Federal | \$527,048,763 | \$596,064,469 | 13.09% |
| Foreign | \$10,153,137 | \$9,166,597 | -9.72% |
| Private | \$114,912,092 | \$139,324,117 | 21.24% |
| State | \$14,835,562 | \$17,705,772 | 19.35% |
| University Flow-through | \$57,401,229 | \$72,785,411 | 26.80% |
| Other Sponsor | \$21,818 | \$3,380,165 | 15392.89% |
| other sponsor | Purpose | ψο,σοσ,1σσ | 10072.0770 |
| Research | \$598,023,313 | \$699,216,477 | 16.92% |
| Training | \$31,788,935 | \$36,296,249 | 14.18% |
| Other | \$161,819,283 | \$167,907,787 | 3.76% |
| | School | , . , . | |
| School of Medicine | \$511,267,195 | \$586,517,519 | 14.72% |
| School of Public Health | \$120,635,410 | \$137,857,117 | 14.28% |
| Emory Primate Center | \$91,683,308 | \$97,346,030 | 6.18% |
| Emory College | \$41,117,507 | \$43,838,494 | 6.62% |
| School of Nursing | \$14,520,348 | \$23,172,979 | 59.59% |
| | Other | | |
| Flow-Through Expenses | \$138,251,875 | \$116,616,477 | -15.65% |
| Outgoing Sub Expenses | \$168,594,264 | \$144,115,646 | -14.52% |
| G 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | #10 401 F00 | ## coo cor | 25.24% |
| Capital Equipment Expenses | \$12,401,580 | \$7,833,285 | -36.84% |
| Square Feet of Lab Space | 789,310 | 789,310 | 0.00% |
| F&A Rate (Research) | 56.00% | 56.00% | 0.00% |
| Industry Trial Rate | 40.50% | 32.00% | |
| Fringe Rate (Fed) | 28.50% | 31.80% | |
| Fringe Rate (Non-Fed) | 27.25% | 27.80% | 2.02% |
| | Personnel ² | | |
| Individuals Paid From | 6.006 | 7 446 | 10.400/ |
| Sponsored Projects | 6,236 | 7,446 | 19.40% |
| PI's Paid From Sponsored Projects | 1,504 | 1,778 | 18.22% |
| | on Sponsored Pr | | |
| | | | |
| Fiscal Year | FY2022 | FY2023 | % Change |
| Total Salary on Sponsored | #0EC 005 1-5 | 4000 555 555 | |
| Projects Federal Salary on Sponsored | \$250,228,150 | \$279,661,004 | 11.76% |
| Projects | \$155,329,723 | \$170,960,139 | 10.06% |

¹Trials based on purpose and independent of award types

² Personnel are Award PI's & Employees Paid on Sponsored Research